Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein

Author(s): Zhuangzhuang Yu, Liwen Zhao, Qi-Dong You

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 15 , Issue 7 , 2015

Become EABM
Become Reviewer


Hepatitis C virus infection is a major health and economic burden worldwide. The standard of care is associated with low sustained virological response and some adverse effects. As an important component of all-oral direct-acting antiviral regimes, inhibitors of NS5A demonstrate potent pan-genotypic activity in vitro and in vivo. This review summarized the discovery and development of NS5A inhibitors, including the early chemotypes for which resistance maps to the NS5A protein, as well as first- and second-generation NS5A inhibitors and other analogues. The mechanism of action of NS5A inhibitors and related clinical trials were also described.

Keywords: Clinical trials, combination therapy, direct-acting antiviral, Hepatitis C virus, NS5A inhibitors, standard of care.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [553 - 581]
Pages: 29
DOI: 10.2174/1389557515666150227100612
Price: $65

Article Metrics

PDF: 32
PRC: 1